| High Serum Ferritin Levels in Newly Diagnosed Patients With Myelodysplastic Syndromes Are Associated With Greater Symptom Severity |
|
International Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity |
|
International Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Heterogeneity in Health-Related Quality of Life of Patients with Aplastic Anemia: A Latent Profile Analysis |
|
Patient Preference and Adherence |
Aplastic Anemia |
| Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Hematopoietic Cell Transplantation With Cryopreserved Grafts for Severe Aplastic Anemia |
|
Biology of blood and marrow transplantation: journal of the America Society of Blood and Marrow Transplantation |
Aplastic Anemia |
| Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. |
|
Biol Blood Marrow Transplant. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML |
|
Aging |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
